Intranasal administration of recombinant human cartilage glycoprotein-39 as a treatment for rheumatoid arthritis: a phase II, multicentre, double-blind, randomised, placebo-controlled, parallel-group, dose-finding trial
Robert B. M. Landewe, Jos G. A. Houbiers, Filip van de Bosch, Joanna in't Hout, Patrick C. P. M. Verschueren, Jan H. Meijerink, Frank H. J. van den Hoogen, Bedrich A. Masek, George A. W. Bruyn, Jacques M. G. W. Wouters, Alexandre E. Voskuyl, Jacob M. van Laar, Johannes W J Bijlsma, Desiree M. F. M. van der Heijde, Ferdinand C. Breedveld, Leo B. A. van de Putte, Andre M. M. Miltenburg*, Filip De Keyser
Research output: Contribution to journal › Article › Academic › peer-review
Fingerprint
Dive into the research topics of 'Intranasal administration of recombinant human cartilage glycoprotein-39 as a treatment for rheumatoid arthritis: a phase II, multicentre, double-blind, randomised, placebo-controlled, parallel-group, dose-finding trial'. Together they form a unique fingerprint.